ライフサイエンスコーパス: cell-free

1 , a rotenoid derivative, was validated using cell-free aGPCR/heterotrimeric G protein guanosine 5'-3-

2 shape-change and enables the development of cell-free and bacterial sensors for diverse applications

3 ctical due to nonspecific extraction of both cell-free and cell-associated viral nucleic acids.

4 We found that transcytosis of both cell-free and cell-associated viruses with diverse envel

5 e key regulatory potential of the gp41 CT in cell-free and cell-to-cell HIV-1 infection, particularly

6 r their sensitivities to a panel of bNAbs in cell-free and cell-to-cell infection assays.

7 tools to further define the contributions of cell-free and cell-to-cell infection in vitro and in viv

8 mechanisms of cell surface receptors in HCV cell-free and cell-to-cell transmission are poorly under

9 lar mechanisms of different receptors in HCV cell-free and cell-to-cell transmission remain elusive.

10 he importance of individual receptors in HCV cell-free and cell-to-cell transmission.

11 N, SR-BI, and LDLR greatly impaired both HCV cell-free and cell-to-cell transmission.

12 achment receptors are important for both HCV cell-free and cell-to-cell transmission.IMPORTANCE The i

13 nging ability and anti-apoptotic activity in cell-free and cellular systems.

14 hosphorylation of the human MNK1a isoform in cell-free and cellular systems.

15 Here we describe a rapid cell-free and detergent-free co-translation method for p

16 was substantially lower than that of SAHA in cell-free and in situ assays.

17 ity of DCFH2 was exemplified in a variety of cell-free and in vitro redox assay systems, including ox

18 with GPI-VHH E4, confers resistance to both cell-free and T cell-T cell transmission of HIV-1 and HI

19 primary CD4 T cells efficiently resist both cell-free and T cell-T cell transmission of HIV-1.

20 ciently neutralizes HIV-1 infection via both cell-free and T cell-T cell transmission.

21 are tolerated by the eukaryotic ribosome in cell-free and whole-cell environments and can be incorpo

22 ong several dominant epitopes, we utilized a cell free antigen processing system and allowed the syst

23 mplete membrane-scaffold could be useful for cell-free applications employing engineered membrane pro

24 ip capable of mechanically inducing circular cell-free areas within confluent cell layers.

25 ls were found along the edge of the circular cell-free areas, thus allowing reliable and reproducible

26 lity of adherent cells to move into adjacent cell-free areas, thus providing information on cell cult

27 t rapid and coordinated movement to generate cell-free areas.

28 RIP catalyzes depurination of 28S rRNAs in a cell-free assay, as well as Howardula rRNA in vitro at t

29 Using an in vitro cell-free assay, we demonstrate that KAE609 directly inh

30 gement in cells and endolysosome fusion in a cell-free assay.

31 as a model cargo protein, we demonstrate in cell-free assays that at least one auxiliary cytosolic f

32 much greater potency than that displayed in cell-free assays with purified protein.

33 interactions were typically performed using cell-free assays with recombinant fusion proteins that c

34 rylated recombinant human Kv 1.5 channels in cell-free assays, and inhibited K(+) currents when intro

35 1.5 channels were phosphorylated by AMPK in cell-free assays, and K(+) currents carried by Kv 1.5 st

36 genetics, protein interaction analyses, and cell-free assays.

37 gand-1 (PSGL-1), both in cell lysates and in cell-free assays.

38 The cell-free assembly method established in this paper reve

39 GSDMD-NT also kills cell-free bacteria in vitro and may have a direct bacter

40 To overcome the intrinsic limitations of cell-free binding studies and usage of recombinant recep

41 have demonstrated a novel mechanism by which cell-free CD34Exo mediates ischemic tissue repair via be

42 A cell-free cellulosomal GH25 lysozyme may provide a bacte

43 ffoldin (ScaG), thus enabling formation of a cell-free cellulosome, whereby ScaG interacts with a div

44 Here, we developed a cell-free CENP-A assembly system that enabled the study

45 the proinflammatory potential of circulating cell-free (cf)DNA in patients undergoing cardiac surgery

46 Tumor DNA from serum (circulating cell free [cf); all patients] and biopsies [160 mg/day a

47 Cell-free (cfDNA) concentrations were found to be signif

48 Cell-free circulating DNA (cfDNA) released from dying ce

49 cribing baseline expression levels for total cell-free circulating RNA from healthy control subjects.

50 plasma samples (n = 75), we demonstrate that cell-free circulating tumor DNA (ctDNA) is directly comp

51 Cell-free circulating tumour DNA (ctDNA) in plasma has b

52 re we report the first de novo synthesis and cell-free cloning of custom DNA libraries in sub-microli

53 e novo synthesis, combinatorial assembly and cell-free cloning of genes, respectively.

54 plasmic reticulum (ER), but we find, using a cell-free coat protein complex II (COPII) vesicle buddin

55 Cell-free components, such as exosomes enriched in prote

56 notype T4) or stimulated with amoeba-derived cell-free conditioned medium.

57 hown to interact with aSyn both in cells and cell free conditions, thus enhancing its aggregation.

58 gene transfer to adult mice, and ex vivo in cell-free conditions, indicating that host co-factors or

59 Under cell-free conditions, rifampicin inhibited oligomer form

60 e and in some cases rather inefficient under cell-free conditions.

61 KD1 phosphorylated AMPKalpha2 at Ser(491) in cell-free conditions.

62 We also developed a cell-free COPII vesicle budding reaction that reconstitu

63 This study explores the effects of coral cell-free culture fluid (CFCF) and autoinducer (a quorum

64 Nup-YC2.1 into Casuarina glauca we show that cell-free culture supernatants of the compatible Frankia

65 as more rapidly degraded than native WRI1 in cell-free degradation assays.

66 he proteasome-dependent turnover of ACD11 in cell-free degradation assays.

67 Cell free DNA (cfDNA) has received increasing attention

68 atic disease, deep sequencing of circulating cell free DNA (cfDNA) obtained from patient's blood yiel

69 Whole-exome sequencing of cell-free DNA (cfDNA) could enable comprehensive profili

70 er 16, 2014, to August 26, 2015, we analyzed cell-free DNA (cfDNA) from baseline plasma samples from

71 Detection of amplification in cell-free DNA (cfDNA) from blood is strongly associated

72 patients with mCRPC, the analysis of plasma cell-free DNA (cfDNA) has recently emerged as a minimall

73 Quantification of cell-free DNA (cfDNA) in circulating blood derived from

74 However, low quantities of cell-free DNA (cfDNA) in the blood and sequencing artifa

75 Circulating cell-free DNA (cfDNA) is emerging as a powerful monitori

76 Cell-free DNA (cfDNA) is shed into the blood by tumor ce

77 een circulating tumor cells (CTCs) or plasma cell-free DNA (cfDNA) on one side and a comprehensive ra

78 arrangements would not have been detected by cell-free DNA (cfDNA) screening.

79 e found in an unbiased manner in circulating cell-free DNA (cfDNA) to predict treatment response in H

80 Cell-free DNA (cfDNA) was isolated from 6 AH samples fro

81 Cellular and cell-free DNA (cfDNA) were isolated from each lavage.

82 ion, immature granulocyte (IG) count, plasma cell-free DNA (cfDNA), and plasma citrullinated histone

83 A tumor-derived fraction of circulating cell-free DNA (cfDNA), isolated from blood samples, cont

84 By deep sequencing cell-free DNA (cfDNA), isolated from circulating blood p

85 Donor-derived cell-free DNA (dd-cfDNA) is a noninvasive test of allogr

86 , which exploits the diagnostic potential of cell-free DNA by determining not only the presence but a

87 Because cell-free DNA from brain and spinal cord tumors cannot u

88 We sequenced 341 cancer-associated genes in cell-free DNA from cerebrospinal fluid (CSF) obtained th

89 Here, analysis of tumor samples and cell-free DNA from patients with advanced prostate cance

90 ingle-stranded DNA sequencing (ssDNA-seq) of cell-free DNA from plasma and other bodily fluids is a p

91 gh massive shotgun sequencing of circulating cell-free DNA from the blood, we identified hundreds of

92 Plasma genotyping of cell-free DNA has the potential to allow for rapid nonin

93 ns and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA me

94 Detection of cell-free DNA in liquid biopsies offers great potential

95 Circulating cell-free DNA is primarily derived from hematopoietic ce

96 t MDS genome would be a major contributor to cell-free DNA levels in MDS patients as a result of inef

97 d to examine the ability of a novel panel of cell-free DNA methylation markers to predict survival ou

98 te that TP53 mutations appear in circulating cell-free DNA obtained from patients with de-differentia

99 tissue-of-origin mapping in the circulating cell-free DNA of 59 patients with lung or colorectal can

100 ic analysis of 1,122 EGFR-mutant lung cancer cell-free DNA samples and whole-exome analysis of seven

101 2878) and genomic data from paired tumor and cell-free DNA samples revealing loss of heterozygosity.

102 e low proportion of tumor-derived DNA in the cell-free DNA scenarios.

103 rimary brain tumor in adults, examination of cell-free DNA uncovered patterns of tumor evolution, inc

104 Cell-free DNA was isolated from 122 of 125 plasma sample

105 Cell-free DNA was isolated from the AH, and sequencing l

106 Cell-free DNA was quantified in plasma samples.

107 NA-elastase and histone-elastase complexes), cell-free DNA, and neutrophil biomarkers were quantified

108 Abundance of tumor-derived DNA in total cell-free DNA, as measured by TP53 mutant allele frequen

109 oplets to represent circulating viral DNA or cell-free DNA.

110 or each case and detected by qPCR within the cell-free DNA.

111 pecificity of 82.0% (95% CI 72.1% to 89.1%) (cell-free donor-derived DNA as noninvasive gold standard

112 vance of the CFTR as a therapeutic target, a cell-free drug screen was established to identify modula

113 However, little is known about the cell-free eccDNA profiles in circulating system such as

114 To characterize plasma cell-free eccDNAs, we performed sequencing analysis in 2

115 s, and neutralizing antibodies compared with cell-free entry.

116 ma activated eugenol derivatives (PAED) in a cell-free environment.

117 Analysis (EMRA) to analyze stability in four cell-free enzymatic systems when enzyme amounts are chan

118 of sourdough wheat bread by the addition of cell-free enzyme extracts (CFEs) from Lactobacillus sanf

119 Effects of I. fumosorosea and cell-free ethyl acetate fractions derived from the fungu

120 logenin by the fungal mycelium as well as by cell-free ethyl acetate fungal extracts.

121 In cell-free experiments, the impacts of the H51Y and E138K

122 Our approach is demonstrated using cell-free expressed bacteriorhodopsin coupled to a quart

123 The cell-free expressed mMOMP-tNLPs contain mMOMP multimers

124 trong linear correlation is observed between cell-free expression levels of holo-metMb variants and t

125 Each droplet contains a cell-free expression system and is connected to its neig

126 Using a cell-free expression system and pulse-proteolysis experi

127 Here we present an efficient cell-free expression system for the site-specific incorp

128 for Escherichia coli protein solubility in a cell-free expression system, 35 sequence-based propertie

129 combinantly expressed all 36 PvTRAgs using a cell-free expression system, and, for the first time, pr

130 By combining nanodiscs and cell-free expression technologies, even completely deter

131 ts have used microfluidics for DNA assembly, cell-free expression, and cell culture, but a combinatio

132 tion of proteins into nanodiscs by combining cell-free expression, noncovalent mass spectrometry, and

133 use single-molecule imaging in a vertebrate cell-free extract to show that synapsis of DNA ends occu

134 analogues of this compound for conversion in cell free extracts of the anaerobic naphthalene degrader

135 pimeloyl-CoA and glutaryl-CoA was proved in cell free extracts, yielding 2,3-dehydropimeloyl-CoA, 3-

136 n at model phospholipid membrane bilayers in cell-free extracts and identified the network of Rho-rec

137 However, it was recently shown that cell-free extracts from yeast and plants could acylate G

138 Using cell-free extracts or purified enzymes, we found that DN

139 distinct DNA polymerase extension profile in cell-free extracts that specifically limits extension to

140 However, the contents of the cell-free extracts used to carry out synthesis are gener

141 roxyphenylacetate decarboxylation in complex cell-free extracts were catalyzed by the same enzyme inc

142 tivity for both substrates was comparable in cell-free extracts, (ii) the two activities displayed id

143 ehavior during chromatographic separation of cell-free extracts, (iii) both activities were irreversi

144 report evidence that in human MGMT-deficient cell-free extracts, CAF-1-dependent packaging of irrepar

145 ed by eIF4E availability in nuclease-treated cell-free extracts.

146 focused on mitochondrial DNA (mtDNA) in the cell free form.

147 th T/F Envs, which was not observed with the cell-free form of the same virus.

148 (iPSCs) provide a new source of therapeutic cells free from the ethical issues or immune barriers of

149 ane fusion in Saccharomyces cerevisiae Using cell-free fusion assays and light microscopy, we find th

150 oscopy, and they can act as compartments for cell-free gene expression.

151 Using a cell-free gene network we programmed molecular interacti

152 Here, we assembled cell-free genetic oscillators in a spatially distributed

153 terization of the high cell density-specific cell-free growth medium demonstrated the presence of a l

154 ial NO signaling, and tissue distribution of cell-free Hb and its scavenger protein complexes.

155 Cell-free Hb depletes nitric oxide (NO) in the vasculatu

156 obin to protect NO signaling by sequestering cell-free Hb in large protein complexes.

157 Extravascular translocation of cell-free Hb into interstitial spaces, including the vas

158 ture of monocytes with exosome-packaged HCV, cell-free HCV, or HCV ssRNA induced differentiation into

159 healthy monocytes with exosome-packaged HCV, cell-free HCV, or HCV ssRNA.

160 Extracellular hemoglobin and cell-free heme are toxic breakdown products of hemolyzed

161 Up to one-third of cell-free heme in plasma from 47 patients with sickle ce

162 14 days in mice) increases plasma levels of cell-free hemoglobin and heme.

163 Nitric oxide (NO) is inactivated by cell-free hemoglobin in a dioxygenation reaction that al

164 nts with severe sepsis and detectable plasma cell-free hemoglobin.

165 d DCs were 4 fold more infective than either cell free HIV-1 or exosomes derived from T-cells.

166 e number of infection events per cell during cell-free HIV-1 infection follows a negative-binomial di

167 tion of CD169(+) myeloid cells in vivo While cell-free HIV-1 infection of IFN-alpha-treated CD4(+) T

168 ity of target cells and analysed datasets of cell-free HIV-1 single and double infection experiments

169 ection on exposure of these cells to primary cell-free HIV-1 supernatants.

170 monstrated that ART can efficiently suppress cell-free HIV-RNA in CVS, despite residual levels of HIV

171 agnostic subnucleosomal particle remnants in cell-free human DNA data as a relic of transcribed genes

172 A cell-free in vitro translation assay containing human ce

173 In a cell-free in vitro translation system, HNP1 powerfully i

174 infection of HIV-1 with T/F Envs compared to cell-free infection of the same virus.

175 ile remaining sensitive to neutralization in cell-free infection.

176 HCV cell-to-cell spread differs from that of cell-free infection.

177 -to-cell transmission, although it inhibited cell-free infection.

178 on capacity relative to the levels seen with cell-free infections.

179 e total number of particles found within the cell-free layers normalized by the total number of parti

180 n Pseudomonas aeruginosa Enzymatic assays in cell-free lysate, together with crude fractionation and

181 d F508del-CFTR more rapidly lost function in cell-free membrane patches and showed altered channel ga

182 and temporal stability in most, but not all, cell-free membrane patches.

183 strated a potential link between circulating cell-free mitochondrial DNA (mtDNA) content and cancers.

184 Conversely, cell-free MLV and VSV virion yields and VSV spread to di

185 The microspheres are attached to cell-free nanofibrous polymer scaffolds that spatially c

186 ort to obtain high affinity reagents and its cell-free nature transcends limitations inherent in prev

187 aromyces cerevisiae as a model, we conducted cell-free organelle fusion assays to show that transport

188 he rapid design, assembly, and validation of cell-free, paper-based sensors for the detection of the

189 ved from hESCs in a microfluidic device with cell-free parental Oka (POka) VZV resulted in latent inf

190 by cell-to-cell contact rather than through cell-free particles.

191 We studied whether noninvasive genotyping of cell-free plasma DNA (cfDNA) is a useful biomarker for p

192 Genotyping of cell-free plasma DNA was performed by using BEAMing.

193 .1% frequency in clonal cell line DNA and in cell-free plasma DNA.

194 The cell-free plasma gap between the red cell and endothelia

195 No such cell-free plasma gap could be detected in the branched d

196 A cell-free plasma gap representing the ECG could be image

197 e the relationship between the production of cell-free plasma hemoglobin and acute kidney injury in i

198 ntravascular venous levels of arginase-1 and cell-free plasma hemoglobin increase immediately after r

199 ube and analyzes the color components of the cell-free plasma layer.

200 , hTetherin expression significantly reduced cell-free plasma viremia and also delayed MoMLV-induced

201 resulted in the specific reduction of MoMLV cell-free plasma viremia but not the number of infected

202 It can be completely replicated using cell-free preparations of purified LDs, where duration o

203 This cell-free process produced on average 1.5 mg of purified

204 Cell-free protein expression allowed (i ) high protein c

205 Cell-free protein expression systems monitored the impac

206 y into supported model lipid membranes using cell-free protein expression.

207 ulation, three-dimensional cell culture, and cell-free protein production.

208 Cell-free protein synthesis (CFPS) has the potential to

209 e we address this limitation by developing a cell-free protein synthesis (CFPS) platform that employs

210 In vitro expression of this protein using cell-free protein synthesis (CFPS) technology in the pre

211 Here, we present an approach of cell-free protein synthesis (CFPS) that provides protein

212 We also demonstrate the robust nature of the cell-free protein synthesis component in the presence of

213 Here, we use cell-free protein synthesis in the presence of oil drops

214 Here, we used cell-free protein synthesis to directly incorporate the

215 that enhances suppression efficiency during cell-free protein synthesis, without significantly impac

216 oteins from mammalian cells, bacteria, and a cell-free protein translation system, we show that the S

217 h an isotope-labeled tyrosine from 100 mL of cell-free reaction extract.

218 e biogenesis and RNA packaging, we devised a cell-free reaction that recapitulates the species-select

219 s required for the sorting of miR-223 in the cell-free reaction.

220 , water-soluble mMOMP-tNLP complex in a 1-ml cell-free reaction.

221 ilized OMV packaged PTE can be utilized as a cell free reagent for long term environmental remediatio

222 Cell-free reconstitution assays show that addition of FB

223 Using cell-free reconstitution with purified Vps13p, we show t

224 es in non-neuronal cells overexpressing Tau, cell-free reconstitutions have not replicated either geo

225 ed in leader cells after the creation of the cell-free region and leader cells are regulated via Notc

226 lls are allowed to migrate into an initially cell-free region.

227 rrogate some of these issues, we optimized a cell-free replication system consisting of mitochondria

228 In this study, we found that plasma cell-free RNA was significantly increased following ceca

229 ng it in a broader field of what is known of cell-free RNAs in communication among different organism

230 llenge in regenerative medicine of achieving cell-free scaffold-based miRNA therapy for tissue engine

231 with the hCMPs than in animals treated with cell-free scaffolds, and the rate of cell engraftment in

232 Cell-free studies have demonstrated how collective actio

233 not observed when tissues were treated with cell-free supernatant from bacterial cultures.

234 The cell-free synthesis in combination with nanodiscs provid

235 with 80S ribosomes capable of initiating the cell-free synthesis of complete proteins in the absence

236 Furthermore, cell-free synthesis of lactose permease during DIB forma

237 The combination of cell-free synthetic biology, nanodisc-technology and non

238 parum proteins prepared using the wheat germ cell-free system (WGCFS).

239 cate cell-bound system and (ii) a simplistic cell-free system composed of a single cohesin-containing

240 capsid assembly and RNA encapsidation in the cell-free system in a manner similar to that seen in mam

241 We have developed a mammalian cell-free system in which HBc is expressed at physiologi

242 Oscillation periods in cells matched the cell-free system results for all networks tested.

243 We characterized in a cell-free system the 'repressilator', a three-node synth

244 Here, we used an Escherichia coli-based cell-free system to express a MOMP protein from the mous

245 mbly during replication and provide a facile cell-free system to study capsid assembly under physiolo

246 e demonstrated both in intact cells and in a cell-free system, and proteasome inhibition or Huwe1 sil

247 In this cell-free system, as in mammalian cells, capsid assembly

248 In a cell-free system, Mediator directly and substantially in

249 ng ability on par with other flavonoids in a cell-free system, Proxison is orders of magnitude more p

250 Using a cell-free system, we recently identified the phosphoinos

251 ferred pathway of ICL repair in a vertebrate cell-free system.

252 n-can be recapitulated in vitro with a yeast cell-free system.

253 n-dUTP near the sites of its initiation in a cell-free system.

254 NAs could support protein translation in the cell-free system.

255 mpared to fresh garlic extract in vitro in a cell-free system.

256 to cognate precursor peptide in cellular and cell free systems.

257 e mechanisms governing EB/tau interaction in cell-free systems and cellular models.

258 is known to mediate actin/MT interactions in cell-free systems but the role of tau in regulating cyto

259 Cell-free systems designed to perform complex chemical c

260 at stabilizes microtubules in neurons and in cell-free systems regulates actin-microtubule interactio

261 ompetitive affinity to TfR evaluated in cell/cell-free systems.

262 tic activity, and processing were defined in cell-free systems.

263 Cell-free TERRA (cfTERRA) could be isolated from the exo

264 ir cargo promising biomarkers of disease and cell-free therapeutic agents.

265 f protective factors that could be useful in cell-free therapeutic approaches for acute brain injury.

266 CM-MSC may provide an effective cell-free therapy for inflammatory arthritis.

267 n reaction pellets composed of freeze-dried, cell-free transcription and translation machinery, which

268 Cell-free transcription assays demonstrated that H3S28ph

269 ssion, characterized inside cells and within cell-free transcription-translation assays.

270 vity of these compounds is investigated with cell-free translation assays using both bacterial riboso

271 Using a cell-free translation system from rabbit reticulocytes p

272 In this study, we used a Drosophila cell-free translation system to directly compare the vel

273 analysis of various modified transcripts in cell-free translation systems, we deconvolute the differ

274 cluding direct cell-to-cell transmission and cell-free transmission, to spread within a host.

275 NA in 89% of patients with confirmed mutated cell-free tumor DNA by plasma analyses (n = 9) within 46

276 enotype human DNA, and identify mutations in cell-free tumor DNA.

277 t this approach may be useful to develop new cell-free vascular grafts for treatment of vascular dise

278 esulting in a 50% increase in infectivity of cell-free viral particles when produced in 293T cells.

279 The relative contributions of cell-free virion circulation and direct cell-to-cell tra

280 To elucidate the roles of tetherin and cell-free virions during in vivo viral dissemination and

281 ll to another without budding and release of cell-free virions, as evidenced by the finding that wher

282 alizing antibody was used to block spread by cell-free virions.

283 hat WT-HCMV produces extremely low titers of cell-free virus but can efficiently infect fibroblasts,

284 72 paired plasma and DBS specimens using the cell-free virus elution method and determined the level

285 A simplified DBS extraction technique for cell-free virus elution using phosphate-buffered saline

286 iated with this scenario suggests a role for cell-free virus in retroviral disease progression.

287 -cell infection in the absence of infectious cell-free virus production.

288 lled tetherin, which may selectively inhibit cell-free virus release.

289 ile tetherin does indeed dramatically reduce cell-free virus spreading, it has little to no effect on

290 t restricted tropism, produce high levels of cell-free virus, and develop susceptibility to natural k

291 d neutralization is highly effective against cell-free virus, antibodies targeting different sites of

292 ile bNAbs potently antagonize infection with cell-free virus, inhibition of HIV-1 transmission from i

293 While bnAbs are highly effective against cell-free virus, they are not induced by current vaccine

294 munization of mice with membrane proteins or cell-free virus.

295 HIV-1 and more difficult to neutralize than cell-free virus.

296 able potency and breadth of coverage against cell-free virus; however, they exhibit a diminished abil

297 Cell-free VZV has been difficult to obtain, both for in

298 e domains of yeast vacuoles both in vivo and cell free, we demonstrate that the domains arise through

299 ate the properties of this enzyme, we used a cell-free wheat germ-based expression system in which mR

300 d from human embryonic stem cells (hESC) and cell-free wild-type (WT) VZV, we demonstrated that neuro